Introducing our Interview with Nate Russart from Alverdon
- Given the acceleration of cell & gene, mRNA, and DNA-based therapies, alongside ongoing pressure around cost, speed, and quality - what do you see as the biggest challenges developers face today when it comes to plasmid DNA process development and manufacturing?
Developers are struggling to rapidly scale plasmid processes from research to GMP while maintaining the high purity, consistency, and regulatory‑ready analytics required for mRNA, AAV, and cell therapy programs. Tight timelines and cost pressure amplify issues like plasmid design, yield loss, and comparability across scales and sites.
- From early research through to GMP and commercial supply, where do you believe Aldevron adds the most value for DNA developers today? And why are those capabilities becoming “must-haves” rather than “nice-to-haves”?
Aldevron delivers value through scalable, phase‑appropriate platforms and early design‑for‑manufacture guidance that help ensure plasmids express, purify, and validate cleanly at any scale. These capabilities have become essential because developers can no longer afford rework, delays, or variability as regulatory expectations and speed‑to‑clinic demands intensify.
- Many developers attending the summit already have established CDMO or CRO relationships in place. From Aldevron’s perspective, is it still worth these teams reassessing their manufacturing strategies?
Yes - technology, capacity, regulatory expectations, and cost structures evolve quickly, so periodic reassessment ensures programs aren’t locked into outdated processes or avoidable risks. Even established partnerships benefit from benchmarking against more efficient, modern, or scalable options.
- As a legacy partner, why do you return, year on year to the DNA Process Development & Manufacturing Summit, to connect with these life sciences leaders?
We return because the summit provides a unique, collaborative environment to share insights, hear developers’ emerging challenges, and help shape best practices across the DNA manufacturing ecosystem. These conversations directly influence how we evolve our technologies, services, and platforms.
- What discussions, technologies, or industry shifts are you most looking forward to exploring at the 3rd DNA Process Deelopment & Manufacturing Summit
Cell-free DNA technologies have been making rapid progressions in the past few years, and the DNA Process Development & Manufacturing Summit has heavily featured these companies. By attending, we are excited to learn more about the most recent updates to these emerging technologies.
- If Aldevron could share one message with DNA, mRNA, and cell & gene therapy developers who may not yet fully understand what’s possible in modern DNA manufacturing, what would that message be?
With our experience in GMP plasmid DNA manufacturing along with our end-to-end capabilities we aim to bring predictability to your manufacturing process while shortening lead times to drug product.
Explore the 2026 Agenda
Catch the latest industry breakthroughs, emerging trends and exclusive insights through our dynamic roundtables and panel discussions.
Partner With Us
As the field rapidly expands, position yourself alongside leading solution providers to ensure your brand stands out as a premier choice amid growing competition.
Join Biopharma Experts
Engage in critical conversations with like-minded attendees from all stages of DNA production and build invaluable connections during dedicated networking sessions.